ARIAD Pharmaceuticals, Inc. is engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company is developing an approach to patients with cancer that addresses aggressive and advanced-stage cancers. Its lead cancer product candidate, deforolimus (previously known as AP23573), is an internally discovered, potent inhibitor of the protein mTOR. Deforolimus was discovered in a research and development program conducted on behalf of ARIAD Gene Therapeutics, Inc., an 80%-owned subsidiary. AP24534, the second product candidate, is a multi-targeted kinase inhibitor believed to have potential applications in cancer, including various forms of leukemia. ARIAD Pharmaceuticals also has a focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. (Source: 10-K)
Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA806 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation. The Company also entered into a master services agreement with Valeant Research & Development, Inc. (Valeant), under which a preclinical program in the field of neuropharmacology will be facilitated on behalf of Valeant. (Source: 10-K)
ConjuChem Biotechnologies Inc. is a biotechnology company. The Company has multiple research programs in-house and has one product in clinical trials. The Company focuses on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DACT) and Pre-formed Drug Affinity Complex (PC-DAC). The Company’s diabetes program has focused on the GLP-1 class of peptides for the treatment of Type 2 diabetes. It is pursuing the development of PC-DACTM: Exendin-4, a GLP-1 homolog combined with its PC-DACTM technology. Its diabetes program has focused on the GLP-1 class of peptides for the treatment of Type 2 diabetes. (Source: ARS)
Cambria Pharmaceuticals is focused on discovering innovative treatments for serious and progressively disabling neurological disorders. The company exploits recent discoveries in the genetic basis of these disorders to engineer novel disease models and identify first-in-class disease-modifying compounds. Cambria leverages collaborative relationships with academic institutions and patient-focused foundations to advance its programs in ALS (Lou Gehrig's disease) and other serious neurological diseases.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory